Free Trial

IQVIA (IQV) Stock Forecast & Price Target

$238.75
-0.04 (-0.02%)
(As of 07/24/2024 ET)

IQVIA - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 17 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 4 have given a hold rating, and 13 have given a buy rating for IQV.

Consensus Price Target

$263.56
10.39% Upside
High Forecast$300.00
Average Forecast$263.56
Low Forecast$220.00

According to the 17 analysts' twelve-month price targets for IQVIA, the average price target is $263.56. The highest price target for IQV is $300.00, while the lowest price target for IQV is $220.00. The average price target represents a forecasted upside of 10.39% from the current price of $238.75.

TypeCurrent Forecast
7/25/23 to 7/24/24
1 Month Ago
6/25/23 to 6/24/24
3 Months Ago
4/26/23 to 4/25/24
1 Year Ago
7/25/22 to 7/25/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
11 Buy rating(s)
Hold
4 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$263.56$258.40$256.80$254.07
Forecasted Upside10.39% Upside18.10% Upside15.67% Upside20.11% Upside
Get IQVIA Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IQVIA Stock vs. The Competition

TypeIQVIAMedical CompaniesS&P 500
Consensus Rating Score
2.76
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside10.37% Upside2,973.08% Upside9.26% Upside
News Sentiment RatingPositive News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/24/2024Jefferies Financial Group
2 of 5 stars
 DowngradeBuy ➝ Hold$266.00 ➝ $242.00+1.34%
7/23/2024Morgan Stanley
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$270.00 ➝ $280.00+16.57%
7/23/2024UBS Group
3 of 5 stars
 Boost TargetBuy ➝ Buy$295.00 ➝ $300.00+24.28%
7/23/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$230.00 ➝ $270.00+12.66%
7/23/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$292.00 ➝ $300.00+25.18%
7/23/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$255.00 ➝ $275.00+12.14%
7/23/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$235.00 ➝ $251.00+2.35%
6/6/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$270.00+23.30%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Davis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$290.00+17.29%
2/15/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
2/13/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$285.00+30.81%
12/11/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$190.00 ➝ $225.00+4.52%
11/13/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$262.00 ➝ $239.00+23.73%
10/10/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$250.00 ➝ $229.00+14.76%
9/6/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$260.00+17.71%
8/2/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$255.00 ➝ $281.00+28.44%
5/1/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$235.00 ➝ $220.00+16.88%
2/13/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$265.00+14.17%
12/6/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$251.00+18.44%
10/18/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$290.00 ➝ $270.00+49.02%
8/18/2022Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$260.00 ➝ $275.00+15.13%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:36 PM ET.

IQV Forecast - Frequently Asked Questions

What is IQVIA's forecast for 2024?

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $263.56, with a high forecast of $300.00 and a low forecast of $220.00.

Should I buy or sell IQVIA stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IQV shares.

Does IQVIA's stock price have much upside?

According to analysts, IQVIA's stock has a predicted upside of 16.15% based on their 12-month stock forecasts.

Has IQVIA been downgraded by Wall Street analysts recently?

Over the previous 90 days, IQVIA's stock had 1 downgrade by analysts.

What analysts cover IQVIA?

IQVIA has been rated by research analysts at Barclays, Evercore ISI, Jefferies Financial Group, Morgan Stanley, Robert W. Baird, The Goldman Sachs Group, Truist Financial, and UBS Group in the past 90 days.

Do Wall Street analysts like IQVIA more than its competitors?

Analysts like IQVIA more than other "medical" companies. The consensus rating score for IQVIA is 2.76 while the average consensus rating score for "medical" companies is 2.72. Learn more on how IQV compares to other companies.


This page (NYSE:IQV) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners